Paediatric-onset autoimmune liver disease: Insights from a monocentric experience
Digestive and Liver Disease · 2025
DOI: 10.1016/j.dld.2024.09.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Franco Curci und 6 weiteren Autor:innen. Beteiligte Einrichtung: NEUROFARBA Department, University of Florence, viale Gaetano Pieraccini 6, 50139 Firenze, Italy. Electronic address: franco.curci@unifi.it. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Hepatitis, Autoimmune. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
BACKGROUND: Autoimmune liver disease (AILD) encompasses autoimmune hepatitis (AIH), autoimmune sclerosing cholangitis (ASC) and primary sclerosing cholangitis (PSC). A unified disease process evolving over time through these entities has been recently suggested. From this perspective, this study aimed to compare the characteristics of childhood-onset AILD at baseline and after a medium-to-long term follow-up period. METHODS: Paediatric-onset cases of AILD diagnosed between 1992 and 2023 at a tertiary-care centre were reviewed. Patients transitioned to adult-care by the time of data collection were asked for clinical updates. RESULTS: Fifty-five patients were included (AIH = 20, ASC =22, PSC =13). AIH, ASC and PSC exhibited increasing age at the onset (AIH to PSC, p < 0.01). The area under the receiver operating characteristic curve for gamma-glutamyltranspeptidase (GGT) combined with alkaline phosphatase/aspartate aminotransferase (ALP/AST) ratio in predicting sclerosing cholangitis was 0.94, with a sensitivity of 86 % and a specificity of 94 %. At the last follow-up (median duration 5,8 years, interquartile range [IQR] 2,9-10,2, n = 45), 15 patients (33 %) developed portal hypertension, 2 patients (4 %) underwent liver transplantation, no patient died. CONCLUSION: A cohort of childhood-onset AILD managed at a single centre reveals a temporal trend in the onset of AIH, ASC and PSC, with progressively older ages. Elevated GGT levels combined with a high ALP/AST ratio predict the diagnosis of sclerosing cholangitis. The occurrence of liver-related adverse events in one-third of patients highlights the progressive nature of paediatric-onset AILD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NEUROFARBA Department, University of Florence, viale Gaetano Pieraccini 6, 50139 Firenze, Italy. Electronic address: franco.curci@unifi.it.
- Meyer Children's Hospital IRCCS, viale Gaetano Pieraccini 24, 50139 Firenze, Italy.
- Department of Health Sciences, University of Florence, viale Gaetano Pieraccini 6, 50139 Florence, Italy.
- Meyer Children's Hospital IRCCS, viale Gaetano Pieraccini 24, 50139 Firenze, Italy; Department of Health Sciences, University of Florence, viale Gaetano Pieraccini 6, 50139 Florence, Italy.
- NEUROFARBA Department, University of Florence, viale Gaetano Pieraccini 6, 50139 Firenze, Italy; Meyer Children's Hospital IRCCS, viale Gaetano Pieraccini 24, 50139 Firenze, Italy.
Förderung
- Ministero della Salute
Zitieren
APA
Curci, F., Rubino, C., Stinco, M., Carrera, S., Trapani, S., Bartolini, E., & Indolfi, G. (2025). Paediatric-onset autoimmune liver disease: Insights from a monocentric experience. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.09.020
Vancouver
Curci F, Rubino C, Stinco M, Carrera S, Trapani S, Bartolini E, et al. Paediatric-onset autoimmune liver disease: Insights from a monocentric experience. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2024.09.020
BibTeX
@article{Curci2025,
author = {Curci, Franco and Rubino, Chiara and Stinco, Mariangela and Carrera, Simona and Trapani, Sandra and Bartolini, Elisa and Indolfi, Giuseppe},
title = {Paediatric-onset autoimmune liver disease: Insights from a monocentric experience},
journal = {Digestive and Liver Disease},
year = {2025},
doi = {10.1016/j.dld.2024.09.020}
}
EUVIMED